两种甲3型流行性感冒疫苗株交叉免疫研究  

Cross immunity study of two different influenza A3 virus vaccine strain

作　　者：张之伦[1] 朱向军[1] 张颖[1] 

机构地区：[1]天津市疾病预防控制中心传染病控制所,300011

出　　处：《中华预防医学杂志》2010年第6期522-525,共4页Chinese Journal of Preventive Medicine

摘　　要：目的 探究2007-2008年度甲3型流行性感冒（简称流感）疫苗2株相似株之间交叉免疫反应的情况.方法 以18～60岁无流感疫苗免疫史的健康人作为受试者,分别接种2种流感裂解疫苗,其中52名接种安尔来福TM,137名接种凡尔灵（R）,采集免疫前、后血清,采用微量血凝抑制（HI）试验检测血清抗体.以免疫后血清抗体阳转率、抗体几何平均滴度（GMT）增长倍数和抗体保护率3项指标进行评价.结果 用广岛株抗原检测,安尔来福TM和凡尔灵（R）的抗体阳转者分别有43名和110名,抗体平均阳转率分别为82.7%（95%CI：69.2%～91.8%）和80.3%（95%CI：72.4%～86.5%）,差异无统计学意义（χ2=0.141,P〉0.05）;用威斯康星株抗原检测,抗体阳转者分别有37名和101名,抗体阳转率分别为71.2%（95%CI：56.7%～82.8%）和73.7%（95%CI：65.4%～80.8%）,差异亦无统计学意义（χ2=0.126,P〉0.05）.用广岛株抗原检测,安尔来福TM和凡尔灵（R）的免疫后抗体GMT增长倍数分别为11.5（95%CI：7.5～17.5）和13.0（95%CI：10.0～16.9）,差异无统计学意义（F=0.497,P〉0.05）;而用威斯康星株抗原检测,分别为9.5（95%CI：6.3～14.3）和10.9（95%CI：8.5～13.7）,差异亦无统计学意义（F=0.554,P〉0.05）.2种疫苗免疫前、后血清抗体保护率,用广岛株抗原检测免疫前安尔来福TM和凡尔灵（R）分别为48.1%和54.7%,免疫后达到98.1%和95.6%,2种疫苗的差异无统计学意义（χ2=0.135～0.673,P值均〉0.05）;用威斯康星株抗原检测,免疫前分别为11.5%和13.9%,免疫后达到80.8%和86.1%,2种疫苗的差异亦无统计学意义（χ2=0.178～0.834,P值均〉0.05）,但是广岛株抗原检测的结果均高于威斯康星株抗原检测的结果（χ2·=7.111～52.155,P值均〈0.01）.结论 WHO推荐的2种季节性流感疫苗相似株之间有良好的交叉免疫反应,但是存在毒株之间的检测系统误差,应采用相同毒株检测.Objective To explore the cross immunity response between two similar strains of influenza A3 virus vaccine from 2007 to 2008.Methods Healthy adults aged 18-60 years old without history of flu vaccination were inoculated AnfluTM（52 cases）or VAXIGRIP（R）（137 cases）influenza split vaccine.A micro-hemagglutination inhibition（HI） assay was used to test the serum specimens collected from the subiects before and after vaccination.The seroconversion rate,geometric mean titer（GMT）and antibody protective rate were used to evaluate the effect.Results The seroconversion rates of AnfluTM and VAXIGRIP（R） tested by A/Hiroshima/52/2005 virus antigen were 82.7%（95%CI：69.2%-91.8%）and 80.3%（95%CI：72.4%-86.5%）respectively and there was no significant difference（χ2=0.141,P〉0.05）.The seroconversion rates of AnfluTM and VAXIGRIP（R） tested by A/Wisconsin/67/2005（H3N2）-like virus antigen were 71.2%（95%CI：56.7%-82.8%） and 73.7%（95%CI：65.4%-80.8%） respectively and there was no significant difference observed （χ2=0.126,P〉0.05）.GMT of AnfluTM and VAXIGRIP（R） tested by A/Hiroshima/52/2005 virus antigen after vaccination inereased 11.5（95%CI：7.5-17.5）times and 13.0（95%CI：10.0-16.9）times without significant difierence（F=0.497,P〉0.05）.GMT of AnfluTM and VAXIGRIP（R） tested by A/Wisconsin/67/2005 （H3N2）-like virus antigen after vaccination inereased 9.5（95%CI：6.3-14.3）and 10.9（95%CI：8.5-13.7）times,and there was no significant difference either（F=0.554,P〉0.05）.The antibody protective rate of two vaccines before and after immunity tested by A/Hiroshima/52/2005 virus antigen were 48. 1% and 54. 7% before vaccination and 98. 1% and 95.6% after vaccination respectively without significant difference （ χ2= 0. 135 - 0. 673,P 〉 0. 05 ）. The antibody protective rates of two vaccines tested by A/Wisconsin/67/2005 （H3N2）-like virus antigen were 11.5% and 13.9% before vaccination and 80. 8% and 86. 1% after vaccination respectively,a

关 键 词：流感病毒A型 H3N2亚型 流感疫苗株 交叉免疫 评价研究 

分 类 号：R511.7[医药卫生—内科学]